[Featured Stock] Prestige Biopharma Hits Upper Limit on News of Joining US Cancer Conquest Project
On the 18th, Prestige BioPharma showed strong performance.
On that morning, Prestige BioPharma's stock price traded at 11,830 KRW, rising to the maximum price limit (30%) in early trading.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Why This Bonus Grade?" Civil Servant Who Assaulted HR Employee... Court Rules Demotion Is Justified
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Prestige BioPharma announced that it will participate in the 'Cancer Moonshot Project' led by U.S. President Joe Biden. The company plans to conduct research related to the diagnosis and treatment of pancreatic cancer in the future.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
